Imagine a giant, coordinated toolkit for fighting viruses that is shared across Europe. Instead of every lab starting from scratch, they've built a single catalog where scientists can quickly find the exact equipment or clinical trial support they need. It's like a specialized 'Amazon' for high-security virus research to stop outbreaks faster.
Drug and vaccine development is often slowed by fragmented research capacities and a lack of coordinated access to high-security labs and clinical samples during outbreaks.
An online comprehensive catalogue of services covering the entire pipeline from structural biology and imaging to clinical trial planning and regulatory advice.
If you are a vaccine developer dealing with a new virus strain — this project developed a unified service catalogue that provides access to structural biology and imaging services. This allows you to accelerate the design of intervention measures using existing European infrastructure.
If you are a diagnostic kit manufacturer dealing with limited access to clinical samples — this project developed a network providing access to clinical samples and immune-monitoring services. This helps you validate your tests against real-world pathogen data more quickly.
If you are a CRO dealing with complex regulatory hurdles for emergency trials — this project developed a system for regulatory advice and clinical trial planning. This reduces the time needed to move a treatment from the lab to the patient.
Based on available project data, the project launched calls for proposals for free of charge transnational access (TNA) to its service offer.
The project integrates 17 major European research infrastructures, providing a massive scale of capacities from structural biology to clinical trials.
Based on available project data, specific IP and licensing terms are not detailed, but the project focuses on providing a service catalogue for user communities.
The service catalogue specifically includes regulatory advice and planning of clinical trials to support the development of diagnostics and vaccines.
The project is designed for responsiveness, utilizing a 'challenge-driven' approach to rapidly support needs-driven research.
The consortium is massive and highly diversified, consisting of 159 partners across 32 countries. While dominated by research institutes (82) and universities (54), there is a strategic industrial presence with 8 industry partners and 9 SMEs. This structure suggests the project is primarily a high-capacity service provider rather than a commercial product developer, acting as a bridge between academic research and industrial application.
Contact the European Research Infrastructure on Highly Pathogenic Agents (ERINHA) in Belgium.
Contact us to identify specific service providers within the ISIDORe network for your R&D pipeline.
